Find Naftopidil manufacturers, exporters & distributors on PharmaCompass

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Virtual Booth

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

10 API Suppliers, 1 USDMF, 7 JDMF, 1 EU WC, 2 KDMF, 4 Listed Suppliers

10 API Suppliers
1 USDMF
7 JDMF
1 EU WC
2 KDMF
4 Listed Suppliers

INTERMEDIATES

5 Intermediates Suppliers

5 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

3 FDF Dossiers, 3 Listed Dossiers

3 FDF Dossiers
3 Listed Dossiers

DIGITAL CONTENT

1 NEWS #PharmaBuzz

media
1 NEWS #PharmaBuzz

ANALYTICAL

1 Analytical Methods

otherMethods
1 Analytical Methods

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

5INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 57149-07-2, Flivas, Kt-611, Naftopidil [inn], Avishot, 1-(4-(2-methoxyphenyl)piperazin-1-yl)-3-(naphthalen-1-yloxy)propan-2-ol

Molecular Formula

C₂₄H₂₈N₂O₃

Molecular Weight

392.5 g/mol

InChI Key

HRRBJVNMSRJFHQ-UHFFFAOYSA-N

FDA UNII

R9PHW59SFN

Naftopidil has been investigated for the treatment of Disorder of Urinary Stent.

1 2D Structure

Naftopidil

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-naphthalen-1-yloxypropan-2-ol

2.1.2 InChI

InChI=1S/C24H28N2O3/c1-28-24-11-5-4-10-22(24)26-15-13-25(14-16-26)17-20(27)18-29-23-12-6-8-19-7-2-3-9-21(19)23/h2-12,20,27H,13-18H2,1H3

2.1.3 InChI Key

HRRBJVNMSRJFHQ-UHFFFAOYSA-N

2.1.4 Canonical SMILES

COC1=CC=CC=C1N2CCN(CC2)CC(COC3=CC=CC4=CC=CC=C43)O

2.2 Other Identifiers

2.2.1 UNII

R9PHW59SFN

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 1-(4-(2-methoxyphenyl)-1-piperazinyl)-3-(1-naphthyloxy)-2-propanol

2.3.2 Depositor-Supplied Synonyms

1. 57149-07-2

2. Flivas

3. Kt-611

4. Naftopidil [inn]

5. Avishot

6. 1-(4-(2-methoxyphenyl)piperazin-1-yl)-3-(naphthalen-1-yloxy)propan-2-ol

7. Bm-15275

8. Naftopidil (flivas)

9. R9phw59sfn

10. Nsc-759293

11. Chembl142635

12. Ncgc00015718-06

13. 1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-(naphthalen-1-yloxy)propan-2-ol

14. Dsstox_cid_25176

15. Dsstox_rid_80725

16. Dsstox_gsid_45176

17. Naftopidilum [latin]

18. Naftopidilum

19. 4-(2-methoxyphenyl)-alpha-[(1-naphthalenyloxy)methyl]-1-piperazineethanol

20. Naftopidil Hydrochloride Hydrate

21. Smr000466346

22. Cas-57149-07-2

23. Naftopidil (unspecified)

24. Unii-r9phw59sfn

25. Brn 0629965

26. Naftopidil,(s)

27. Flivas (tn)

28. Naftopidil [mi]

29. Naftopidil [jan]

30. Prestwick0_000975

31. Prestwick1_000975

32. Prestwick2_000975

33. Prestwick3_000975

34. (+-)-1-(4-(2-methoxyphenyl)piperazinyl)-3-(1-naphthyloxy)propan-2-ol

35. Naftopidil (jp17/inn)

36. (rs)-1-(4-(2-methoxyphenyl)-1-piperazinyl)-3-(1-naphthyloxy)-2-propanol

37. 4-(2-methoxyphenyl)-alpha-((1-naphthalenyloxy)methyl)-1-pioerazineethanol

38. Cid_4418

39. Naftopidil [mart.]

40. Naftopidil [who-dd]

41. Lopac0_000941

42. Regid_for_cid_4418

43. Bspbio_001009

44. Mls000759459

45. Mls001424117

46. Schembl113215

47. Spbio_002920

48. Bpbio1_001111

49. Dtxsid5045176

50. Bdbm50773

51. Chebi:31891

52. Cid_6603044

53. Hms2051b09

54. Hms2089g07

55. Hms3393b09

56. Hms3655h21

57. Hms3884p07

58. Pharmakon1600-01506024

59. Bcp21786

60. Hy-b0391

61. 3-(naphthalen-1-yloxy)propan-2-ol

62. Tox21_110205

63. Bbl028454

64. Mfcd00242741

65. Nsc759293

66. S2126

67. Stl372645

68. (+-)-4-(o-methoxyphenyl)-alpha-((1-naphthyloxy)methyl)-1-piperazineethanol

69. 1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-naphthalen-1-yloxypropan-2-ol

70. 1-pioerazineethanol, 4-(2-methoxyphenyl)-alpha-((1-naphthalenyloxy)methyl)-

71. Akos002279617

72. Akos016328058

73. Tox21_110205_1

74. Bcp9000976

75. Ccg-100935

76. Ccg-205022

77. Db12092

78. Fe-0209

79. Nc00185

80. Nsc 759293

81. Sb19321

82. Sdccgsbi-0050915.p003

83. Ncgc00015718-04

84. Ncgc00015718-05

85. Ncgc00015718-08

86. Ncgc00015718-09

87. Ncgc00015718-10

88. Ncgc00015718-12

89. Ncgc00015718-25

90. Ncgc00024672-03

91. Ncgc00024672-04

92. Bn164631

93. 1-(4-(2-methoxyphenyl)piperazin-1-yl)-

94. Sbi-0050915.p002

95. Ab00514643

96. Ft-0630696

97. N0832

98. Sw196570-4

99. 49n072

100. D01674

101. Ab00489961-18

102. Ab00489961-19

103. Ab00489961_20

104. Ab00489961_21

105. A831328

106. Q6958243

107. Brd-a01787639-300-03-7

108. Brd-a01787639-300-04-5

109. 1-[4-(2-methoxyphenyl)piperazinyl]-3-(1-naphthyloxy)propan-2-ol

110. 1-[4-(2-methoxyphenyl)-1-piperazinyl]-3-(1-naphthalenyloxy)-2-propanol

111. 1-[4-(2-methoxyphenyl)piperazino]-3-(1-naphthoxy)propan-2-ol;hydrochloride

112. Bm-15275; Kt-611; Bm 15275; Kt 611; Bm15275; Kt611

113. (+/-)-4-(o-methoxyphenyl)-.alpha.-((1-naphthyloxy)methyl)-1-piperazineethanol

114. 1-[4-(2-methoxyphenyl)-1-piperazinyl]-3-(1-naphthalenyloxy)-2-propanol;hydrochloride

115. 1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-naphthalen-1-yloxy-propan-2-ol;hydrochloride

116. 1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-naphthalen-1-yloxypropan-2-ol;hydrochloride

2.4 Create Date

2005-03-25

3 Chemical and Physical Properties

Molecular Formula	C₂₄H₂₈N₂O₃
Molecular Weight	392.5 g/mol
XLogP3	4.1
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	7
Exact Mass	392.20999276 g/mol
Monoisotopic Mass	392.20999276 g/mol
Topological Polar Surface Area	45.2 Å²
Heavy Atom Count	29
Formal Charge	0
Complexity	483
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	1
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Antihypertensive Agents

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)

Adrenergic alpha-Antagonists

Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (See all compounds classified as Adrenergic alpha-Antagonists.)

Calcium Channel Blockers

A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)

Platelet Aggregation Inhibitors

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)

API SUPPLIERS